Zenith Capital Corp
OTC:ZHCLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (18.6), the stock would be worth $0 (100% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | $0.05 |
0%
|
| Industry Average | 18.6 | $0 |
-100%
|
| Country Average | 10.9 | $0 |
-100%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Zenith Capital Corp
OTC:ZHCLF
|
176.7k USD | 0 | 0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 18.3 | 83.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 18.3 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 16 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 30 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 15.7 | 17.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 119.2 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 11.7 | 30.3 |
Market Distribution
Other Multiples
Zenith Capital Corp
Glance View
Zenith Capital Corp. is a biotechnology investment company, which engages on the discovery and development of novel therapeutics. The company is headquartered in Calgary, Alberta. The company went IPO on 2020-03-06. The Company’s subsidiary, Zenith Epigenetics Ltd. is a clinical stage biotechnology company, which is focused on the discovery and development of therapeutics for the treatment of cancer and other disorders with unmet medical need. Zenith Epigenetics Ltd. is developing various combinations of extra terminal domain (BET) inhibitors with other targeted agents. The lead compound, ZEN-3694, is in development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer. In collaboration with Pfizer, the Company is advancing ZEN-3694 in combination with talazoparib in a Phase II study in triple negative breast cancer (TNBC) patients, which do not have a hereditary BRCA1/2 mutation. This is expected to greatly expand the patient population addressed by poly adenosine diphosphate-ribose polymerase (PARP) inhibitors.
